| Literature DB >> 32711433 |
Mark Rector Charles1, Syed Tasleem Raza1, Rolee Sharma2, Pushpendra Pratap1, Ale Eba1, Manvendra Singh3.
Abstract
BACKGROUNDS: Cervical cancer (CC) is one of the leading cause of death in women worldwide, HPV infection is the major risk factor in the disease development, 0and however other risk factor such as chemical carcinogens, genetic susceptibility and altered immune system are also a cause of the disease progression. In the light of the above statement we studied the base excision repair pathway (BER).Entities:
Keywords: APE-1; Base excision repair; Cervical cancer; XRCC1; gene polymorphism
Mesh:
Substances:
Year: 2020 PMID: 32711433 PMCID: PMC7573399 DOI: 10.31557/APJCP.2020.21.7.2061
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Primer Sequence and Length of PCR Products
| Primers | Sequence | PCR Product Size |
|---|---|---|
|
| F1,5’ CCCTTTGGCTTGAGTTTTG3’ | 238,138,75 |
|
| F1, 5-CCT ACG GCA TAG GTG AGA CC-3 | 460,205,63 |
|
| F1,5’- TCC CTG CGC CGC TGC AGT TTC T-3’, | 63,04,47,222 |
|
| F1, 5-CCT ACG GCA TAG GTG AGA CC-3 | 360, 236,167 |
General Information Pertaining of Controls and Cervical Cancer Patients Included in the Study
| Variables | Control n=109 | % | Case n=102 | % |
|
|---|---|---|---|---|---|
| Age (years) (mean +SD) | 45.37+10.4 | 49.1+13.1 | 0.68 | ||
| Tobacco consumption | |||||
| Tobacco | 4 | 4.34 | 18 | 18.35 | 0.001 |
| Non -Tobacco | 103 | 95.6 | 81 | 81.14 | |
| HPV Infection | |||||
| HPV-Positive | 17 | 15.6 | 91 | 89 | 0.001 |
| HPV-Negative | 92 | 84 | 8 | 11.26 |
Distribution of Genotypes and Allele Frequencies of XRCC1( Arg194Trp, Arg280His, Arg399Gln) and APE-148 Polymorphism in Cervical Cancer Patients and Controls
| Control (109) no(%) | Case (102) no(%) | OR |
| 95% CI | ||
|---|---|---|---|---|---|---|
|
| ||||||
| Genotype | CC | 32 (29.53%) | 21 (20.58%) | Refrence | ||
| CT | 13 (11.92%) | 11 (11.76%) | 1.29 | 0.61 | (3.41-0.49) | |
| TT | 21 (19.26%) | 33 (32.35%) | 2.39 | 0.03 | (5.20-1.10) | |
| CT+TT | 34 (31.19%) | 44 (43.13%) | 1.97 | 0.05 | (4.01-0.97) | |
| Alleles | C | 77 (70.64%) | 53 (51.96%) | Reference | ||
| T | 55 (50.45%) | 77 (75.49%) | 2.03 | 0.004 | (3.33-1.24) | |
|
| ||||||
| Genotype | GG | 29 ( 26.6%) | 13 (12.73%) | Reference | ||
| GA | 9 (8.25%) | 7 (6.87%) | 1.74 | 0.35 | (5.67-0.53) | |
| AA | 8 (7.33%) | 15 (14.7%) | 4.18 | 0.01 | (11.58-1.32) | |
| GA+AA | 17 (15.29%) | 22 (21.56%) | 2.89 | 0.02 | (7.17-1.16) | |
| Alleles | G | 67 (61.46) | 33 (32.35%) | Reference | ||
| A | 25 (22.93%) | 37 (36.25%) | 3 | 0.001 | (5.79-1.56) | |
|
| ||||||
| Genotype | GG | 27 (24.77%) | 14 (13.72%) | Reference | ||
| GA | 25 (22.93%) | 17 (16.66%) | 1.31 | 0.55 | (3.20-0.54) | |
| AA | 14 (12.84%) | 25 (24.5%) | 3.44 | 0.01 | (8.64-1.37) | |
| GA+AA | 39 (35.77%) | 42 (41.17%) | 2.13 | 0.05 | (4.65-0.98) | |
| Alleles | G | 79 (72.47%) | 45 (44.11%) | Reference | ||
| A | 53 (48.62%) | 67 (65.68%) | 2.22 | 0.002 | (3.71-1.33) | |
| APE 148 | ||||||
| Genotype | TT | 42 (38.52%) | 47 (46%) | Rreference | ||
| TG | 39 (36.7%) | 27 (26.51%) | 0.63 | 0.14 | ( 1.18-0.33) | |
| GG | 11 (10.1%) | 3 (3.4%) | 0.2 | 0.03 | (0.97-0.04) | |
| TG+GG | 49 (53.4%) | 30 (32%) | 0.55 | 0.05 | (1.01-0.30) | |
| Alleles | T | 124 (57.8%) | 122 (60%) | Reference | ||
| G | 61 (28.1%) | 58 (19.11%) | 0.91 | 0.87 | (1.50-0.62) |
CI, confidence interval; OR, odds ratio, p >0.05